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The ability of cancer cells to invade surrounding 
normal tissues at primary sites requires a series of 
early events, including rapid reorganization of cell 
cytoskeleton, formation and extension of plasma 
membrane protrusions in response to chemotac-
tic signals, stable focal adhesion (FA)–mediated 
cell attachment to extracellular matrix near the 
leading edge of the protrusions, and translocation 
of the cell body forward aided by release of FAs at 
the cell rear. FAs act as signaling centers in which 
multiple dynamic protein–protein interactions 
occur to regulate the assembly and disassembly of 
FA sites, which are essential for the control of cell 
movement and migration.
In contrast to FA assembly, which is pri-
marily driven by the GTP-bound Rho GTPases 
(Ridley and Hall, 1992; Hall, 1998), the dy-
namic of disassembly of FA protein complexes 
is not fully understood. Earlier studies pinpoint 
a key role for cell cytoskeleton signaling both 
in FA formation and removal at FA sites (for 
review see Webb et al., 2002). In particular, 
actin-binding proteins such as filamins are cru-
cial for cell adhesion to extracellular matrix and 
cell movement. They mediate cross-linking of 
cortical cytoplasmic actin into a dynamic three-
dimensional structure and participate in the 
CORRESPONDENCE  
Moulay A. Alaoui-Jamali: 
moulay.alaoui-jamali@mcgill.ca
Abbreviations used: EGF, epi-
dermal growth factor; EGFP, 
enhanced GFP; ERK, extracel-
lular signal-regulated kinase; 
EYFP, enhanced YFP; FA, focal 
adhesion; FAK, FA kinase; 
MAPK, mitogen-activated 
protein kinase; MBP, myelin 
basic protein; PSR, pSuper 
retro; shRNA, short hairpin 
RNA; siRNA, small interfering 
RNA; TMA, tissue microarray.
Filamin A regulates focal adhesion 
disassembly and suppresses breast cancer cell 
migration and invasion
Yingjie Xu,1,2,3,4 Tarek A. Bismar,5 Jie Su,1,2,3,4 Bin Xu,1,2,3,4  
Glen Kristiansen,6 Zsuzsanna Varga,6 Lianghong Teng,5  
Donald E. Ingber,7,8,9,10 Akiko Mammoto,7,8,9 Rakesh Kumar,11  
and Moulay A. Alaoui-Jamali1,2,3,4
1Lady Davis Institute for Medical Research and 2Segal Cancer Centre, Jewish General Hospital, 3Department of Medicine  
and 4Department of Oncology, Faculty of Medicine, McGill University, Montreal, Quebec H3T 1E2, Canada
5Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Calgary, Calgary, Alberta T2L 2K8, 
Canada
6Institute of Surgical Pathology, University Hospital Zurich, 8091 Zurich, Switzerland
7Vascular Biology Program, 8Department of Pathology, and 9Deparment of Surgery, Children’s Hospital Boston, Harvard 
Medical School, Boston, MA 02115
10Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA 02115
11Department of Biochemistry and Molecular Biology, The George Washington University Medical Center, Washington,  
DC 20037
The actin cross-linking protein filamin A (FLNa) functions as a scaffolding protein and 
couples cell cytoskeleton to extracellular matrix and integrin receptor signaling. In this 
study, we report that FLNa suppresses invasion of breast cancer cells and regulates focal 
adhesion (FA) turnover. Two large progression tissue microarrays from breast cancer pa-
tients revealed a significant decrease of FLNa levels in tissues from invasive breast cancer 
compared with benign disease and in lymph node–positive compared with lymph node–
negative breast cancer. In breast cancer cells and orthotopic mouse breast cancer models, 
down-regulation of FLNa stimulated cancer cell migration, invasion, and metastasis forma-
tion. Time-lapse microscopy and biochemical assays after FLNa silencing and rescue with 
wild-type or mutant protein resistant to calpain cleavage revealed that FLNa regulates FA 
disassembly at the leading edge of motile cells. Moreover, FLNa down-regulation enhanced 
calpain activity through the mitogen-activated protein kinase–extracellular signal-regulated 
kinase cascade and stimulated the cleavage of FA proteins. These results document a 
regulation of FA dynamics by FLNa in breast cancer cells.
© 2010 Xu et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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anchoring of several plasma membrane proteins, including 
integrins, to the cortical actin. These functions are essential 
for cell locomotion and migration in response to microenvi-
ronmental stimuli. Three highly conserved filamin isoforms 
exist in mammals: filamin A (FLNa), FLNb, and FLNc. These 
isoforms have a wide tissue expression, although FLNc is 
more restricted to skeletal and cardiac muscles in adults (Sheen 
et al., 2002; Feng and Walsh, 2004). Notably, FLNa is the 
dominant mammalian nonmuscle isoform of actin-binding 
proteins, which organizes actin filaments into orthogonal 
networks (Gorlin et al., 1990; Stossel et al., 2001; Nakamura 
et al., 2002).
The molecular function of FLNa in cell chemotaxis re-
mains debated and seems to vary depending on FLNa expres-
sion levels and its interacting partners, particularly those that 
share overlapping binding sites on integrins such as talin. Of 
biological significance, FLNa missense mutations are associ-
ated with a wide spectrum of human disorders where loss of 
function mutations are regarded as a cause of impaired neural 
cell migration in response to microenvironmental cues, in ad-
dition to causing defects in the vascular system (Cunningham 
et al., 1992; Eksioglu et al., 1996; Fox et al., 1998; Sheen et al., 
2002; Nagano et al., 2004; Feng et al., 2006). However, a role of 
FLNa in cell migration is contradicted by other studies showing 
that locomotion of cells derived from distinct FLNa knock-
out mice is not significantly different from WT cells (Feng 
et al., 2006; Hart et al., 2006). Moreover, overexpression of 
FLNa in FLNa-deficient M2 cells (Cunningham et al., 1992) 
or mouse cortical neurons (Sarkisian et al., 2006) resulted in 
inhibition rather than stimulation of cell migration. Strong 
binding of FLNa to integrin was reported to prevent cell mi-
gration (Pfaff et al., 1998; Calderwood et al., 2001). Another 
study using the HT-1080 human fibrosarcoma cells demon-
strated that FLNa knockdown did not affect the speed but 
rather the initiation of migration (Baldassarre et al., 2009).
In this study, we provide evidence that low levels of FLNa 
correlate with human breast cancer progression. We report 
that FLNa down-regulation stimulates breast cancer cell mi-
gration and cell invasion in vitro and promotes metastasis 
formation in xenograft breast cancer mouse models. We dem-
onstrate that FLNa regulates FA disassembly via a calpain- 
dependent mechanism.
RESULTS
Low expression levels of FLNa correlate with breast  
cancer progression
To examine the potential clinical relevance of FLNa to cancer 
progression, we investigated its expression using a human 
breast tissue microarray (TMA) from cancer patients with 
progressive breast disease: benign, in situ, and invasive breast 
carcinoma. Immunohistochemistry analysis using a monoclo-
nal antibody that recognizes the N-terminal portion of FLNa 
revealed an inverse correlation between FLNa high expres-
sion levels and breast cancer progression (Fig. 1 A). The nor-
malized mean epithelial expression of FLNa in invasive breast 
cancer (0.30 ± 0.625) was significantly lower than localized 
Figure . Low FLNa expression levels are correlated with breast 
cancer progression. (A) FLNa expression levels were examined by blinded 
pathology analysis of TMA (n = 222 samples) from breast cancer patients 
with progressive disease: benign, in situ carcinoma, and invasive carci-
noma. Histogram represents normalized mean of epithelial expression of 
FLNa levels (confidence intervals [CI] of 95% ± SEM) using a monoclonal 
antibody that recognizes the FLNa N terminus. Images below the histo-
gram correspond to representative immunostaining of breast cancer  
tissue cores from progressive breast cancers. Differences among the three 
groups were compared with one-way analysis of variance and the post-
hoc Tukey honestly significant difference test for multiple comparisons  
(*, P < 0.005). (B) An independent TMA was assembled from a total of 258 
lymph node (LN)–positive and –negative breast cancer patients’ samples. 
Histogram shown represents normalized mean of epithelial expression of 
FLNa (confidence intervals of 95% ± SEM) as determined by quantitative 
evaluation of immunostaining. A significant decrease of FLNa expression 
was observed in lymph node–positive (n = 127) versus lymph node– 
negative breast cancer (n = 155; *, P = 0.008).
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gold particles to the cell surface. Compared with PSR control 
cells, the mean area of migration increased by 2.5-fold in 
FLNa-silenced cells (Fig. 3 D).
Inhibition of FLNa accelerates FA disassembly
To understand the mechanism by which FLNa regulates can-
cer cell migration, we investigated FA turnover in matched 
control and FLNa shRNA–expressing BT-20 cells cultured 
on either fibronectin- or collagen-coated plates. Western blot 
analysis revealed a consistent decrease in FA kinase (FAK)–
pY397 (the ratios of phosphorylated/total FAK were 0.617 ± 
0.09 and 0.386 ± 0.073 for control and FLNa-silencing cells, 
respectively; P < 0.05) and paxillin-pY118 phosphorylation 
(the ratios of phosphorylated/total paxillin were 0.632 ± 
0.079 and 0.407 ± 0.088 for control and FLNa-silenced cells, 
respectively; P < 0.05, n = 4) in FLNa shRNA–expressing 
in situ breast cancer (0.69 ± 0.998) and benign tissue (1.52 ± 
0.344; P < 0.005). In contrast to FLNa, immunohistochemi-
cal analysis using a polyclonal antibody against FLNb revealed 
a positive correlation between high expression levels of FLNb 
in epithelial cells and breast cancer progression (Fig. S1 A). 
The correlation between low expression levels of FLNa and 
invasiveness was also observed in an independent TMA of 258 
lymph node–positive and –negative breast cancer patients’ 
samples. Expression levels of FLNa were significantly de-
creased in lymph node–positive breast cancer (n = 127) versus 
lymph node–negative cancer (n = 155; mean epithelial expres-
sion of FLNa was 0.89 ± 0.21 and 0.66 ± 0.14 for lymph node–
negative and –positive breast cancer, respectively; P = 0.008; 
Fig. 1 B). A similar inverse correlation between FLNa ex-
pression levels and lymph node status was observed using 
an antibody that recognizes phospho-FLNa-Ser2152 (P = 
0.004; Fig. S1 B).
To further investigate the inverse correlation between low 
levels of FLNa expression and cancer invasiveness, we exam-
ined the impact of FLNa down-regulation on cancer progres-
sion using preclinical orthotopic breast cancer models. We 
compared the incidence of lung metastases after implantation 
of MDA-231-ErbB2 cells expressing either scrambled short 
hairpin RNA (shRNA; pSuper retro [PSR] scrambled) or 
FLNa shRNA (PSR-FLNa) into the mammary fat pad of 
SCID mice. A significant increase in the number of lung me-
tastases was observed in the FLNa-silenced group compared 
with control mice (147 ± 17.68 vs. 293.33 ± 62.52 for PSR 
scrambled and PSR-FLNa, respectively; P < 0.005; Fig. 2). 
In a similar manner, silencing FLNa in the breast cancer cell 
line BT-20 enhanced the incidence of lung metastases after 
implantation into the mammary fat pad compared with con-
trol cells expressing scrambled shRNA (unpublished data).
Inhibition of FLNa stimulates breast cancer cell motility  
and invasion
To investigate the function of FLNa in cancer progression, we 
used a panel of breast cancer cell lines with distinct invasive 
properties (MCF-7-ErbB2, MDA-231, MDA-231-ErbB2, 
and BT-20 cells) and their matched pairs in which FLNa was 
stably inhibited using an RNA interference approach. FLNa-
specific shRNA expression resulted in >90% inhibition of 
endogenous FLNa protein compared with control cells (PSR; 
Fig. 3 A and Fig. S2). In contrast, no obvious compensation by 
FLNb expression was seen. In comparison with PSR control 
cells, the Boyden chamber assay revealed a significant stimula-
tion of cell invasion after FLNa inhibition (P < 0.01 for all 
the cell types tested; Fig. 3 B).
In a similar manner, cell motility using the wound healing 
assay and focusing on the MDA-231-ErbB2 cells revealed 
that 80% of the wound was closed within 24 h by FLNa- 
silenced cells compared with 34% only for control cells 
(Fig. 3 C). Consistent with these results, phagokinetic track 
assay indicated an increase in the motility of FLNa-silenced 
cells compared with control cells, as revealed by the free tracks 
generated by phagokinetic ingestion or attachment of the 
Figure . Inhibition of FLNa promotes cancer progression to  
metastases in a preclinical orthotopic breast cancer model. MDA-
231-ErbB2 cells expressing empty retroviral particles (PSR) or particles 
containing control scrambled shRNA (PSR-scramble) or FLNa-specific 
shRNA (PSR-FLNa) were implanted into the mammary fat pad of 10 SCID 
mice per cell type. Primary tumors were excised when they reached a size 
of 0.6–0.8 cm3, and animals were kept under observation for a period of  
3 mo to allow metastasis formation. Mice were then subjected to autopsy, 
and lung metastases were examined. (A) Representative Western blot 
analysis of total cell extracts from MDA-231-ErbB2 tumor cells isolated 
from lung metastatic nodules confirming efficient stability of FLNa knock-
down after in vivo implantation. GAPDH was used as an internal control. 
MM, molecular mass. (B) Graphs show the mean number of lung metasta-
ses ± SEM (*, P < 0.005), and images show representative lungs with  
metastatic nodules. Arrows indicate surface lung metastatic nodules.  
Bar, 8 mm.
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at 2 h. In comparison with control 
cells, FLNa-silenced cells showed a rapid 
loss of paxillin-pY118 (more obvious 
at 15 min after nocodazole washout; 
Fig. 4 B). Similar results were obtained 
using an antibody against FAK-pY397 
and vinculin (unpublished data). The 
areas of FAs formed under each con-
dition were quantified in Fig. 4 C. FLNa 
silencing induced a strong reduction 
of FA area at 15 min after nocodazole washout (85% from 
0-min level compared with 35% for control cells; P < 0.01).
To confirm the impact of FLNa on FA disassembly, we mon-
itored the level of paxillin-pY118 and FAK-pY397 of control 
and FLNa-silenced cells by Western blot analysis. Interestingly, 
the levels of both paxilin-pY118 and FAK-pY397 were de-
creased after nocodazole washout (Fig. 4 D), and this correlated 
with the loss of FA shown by immunofluorescence in Fig. 4 B. 
Densitometry quantification of FAK-pY397 and paxillin-
pY118 is reported in Fig. 4 D (right). Similar results were ob-
served in other breast cancer cell types, including MDA-231-ErbB2 
cells (Fig. S3).
cells compared with control cells (Fig. 4 A). Next we investi-
gated FA turnover by first using the nocodazole-based assay. 
Treatment of cells with the microtubule-disrupting agent no-
codazole activates RhoA GTPase, which then stimulates the 
formation of FAs. Nocodazole washout initiates a wave of 
microtubule regrowth and transient FA disassembly that is 
followed by FA recovery, a process which is FAK dependent 
(Ezratty et al., 2005; Yeo et al., 2006). Exposure of serum-
starved control cells to nocodazole induced FA formation fol-
lowed by FA disassembly and reassembly upon nocodazole 
washout (Fig. 4 B). FA reappearance after nocodazole wash-
out was observed starting from 1 h and became more obvious 
Figure . Inhibition of FLNa stimulates 
breast cancer cell migration and invasion. 
(A) Western blot showing FLNa and FLNb ex-
pression in MDA-231, MDA-231-ErbB2, MCF-
7-ErbB2, and BT-20 cells stably engineered to 
express FLNa-shRNA (PSR-FLNa) and their 
matched control cells expressing PSR puro 
vector alone (PSR). GAPDH was used as an 
internal control. MM, molecular mass.  
(B) Invasion of MDA-231, MDA-231-ErbB2,  
MCF-7-ErbB2, and BT-20 cells expressing PSR 
(control) and FLNa-shRNA using the Boyden 
chamber assay as described in Materials and 
methods. Bar graph represents the mean 
number of invaded cells (*, P < 0.01), and 
representative images of invasive cells on the 
membrane are shown. Results are expressed 
as the mean ± SD of five independent experi-
ments and five fields per condition. (C) Cell 
migration analyzed by the wound healing 
assay. MDA-231-ErbB2 cells were wounded 
and monitored over 24 h to determine the 
rate of migration into the scratched area. Bar 
graph represents the mean ± SD of five inde-
pendent experiments, and representative im-
ages of the wound captured at different time 
points are shown. (D) Cell motility analyzed 
using the phagokinetic track assay as de-
scribed in Materials and methods. Bar graphs 
shows a quantification (mean ± SD) of the 
cleared areas from four independent experi-
ments with >100 tracks assessed per experi-
ment (*, P < 0.01). Images on the right 
represent brightfield microscopic images of 
the cleared phagokinetic areas. Bars: (B and C) 
150 µm; (D) 120 µm.
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To further confirm the impact of FLNa on FA turnover, 
we investigated FA dynamics by time-lapse video spinning 
disk confocal microscopy using enhanced YFP (EYFP)–tagged 
paxillin (EYFP-paxillin) as an FA marker. In protrusive re-
gions of FLNa-silenced cells, the intensity of paxillin adhe-
sions decreased and eventually disappeared as new adhesions 
formed at the leading edge. FLNa-silenced cells showed a 
higher migratory rate and rapid disassembly of FAs compared 
with matched control cells, which have more stable FA struc-
tures (Fig. 5, A and B; and Videos 1 and 2). Further quantifica-
tion of the duration of EYFP-paxillin intensity in forming or 
disassembling FAs was performed based on methodology re-
ported by Franco et al. (2004b). A persistence of EYFP-paxillin 
in adhesion complexes of control cells was observed for an 
extended duration compared with FLNa-silenced cells (P < 
0.01; Fig. 5 C). Moreover, the rate of EYFP-paxillin from ad-
hesion sites (quantified by integrating the EYFP-paxillin flu-
orescent intensity in individual adhesions over time) was 
increased in FLNa-silenced cells compared with control cells 
(P < 0.01; Fig. 5 D). Similar results were obtained when cells 
were transfected with the FA marker EYFP-vinculin (unpub-
lished data).
Regulation of FA turnover by FLNa is calpain dependent
The mechanism by which cytoskeletal proteins regulate FA 
dynamics is not fully understood. Microtubule disruption has 
been shown to induce Rho activation and the formation of 
FAs and stress fibers (Danowski, 1989; Bershadsky et al., 1996; 
Enomoto, 1996). Calpain is required for microtubule-mediated 
disassembly of adhesive complex sites after nocodazole wash-
out (Bhatt et al., 2002). Calpain is a calcium-dependent pro-
tease that catalyzes the cleavage of several cytoskeleton and 
FA proteins, including filamin, talin, FAK, paxillin, and Src. 
This proteolytic activity is required for the promotion of FA 
turnover (Potter et al., 1998) and induction of cell motility 
(Yan et al., 2001; Carragher et al., 2003; Robles et al., 2003).
Using the luminescence Calpain-Glo assay, we observed 
that normalized calpain activity was increased in both FLNa-
silenced MDA-231-ErbB2 and BT-20 cells compared with 
their respective control cells. This effect was significant for 
MDA-231-ErbB2, in which a 25% increase in calpain activity 
was observed in FLNa-silenced cells compared with control 
cells (P < 0.01; Fig. 6 A). Next, we used degraded type I col-
lagen to stimulate calpain-mediated cleavage of FA proteins 
(Carragher et al., 1999). We confirmed that calpain induced a 
rapid cleavage of FLNa, talin, FAK, Src, and paxillin after in-
cubation with degraded collagen (Fig. 6 B). Calpain induced 
cleavage products of 190 kD for FLNa, 190 kD for talin, 
90 and 35 kD for FAK, and 52 and 47 kD for Src. 
Because the initial cleavage products of FA proteins can be 
further processed by calpain (e.g., cleavage of the 90-kD 
product of FAK can generate 50- and 40-kD products; Fig. S4; 
Carragher et al., 1999), we compared levels of calpain- 
induced cleavage of full-length proteins. In comparison with 
control cells, FLNa-silenced cells (PSR-FLNa) expressed less 
native calpain substrates, particularly FAK and paxillin. 
Although we could not detect the cleavage products of paxil-
lin (55 kD) because of the limited antibody’s specificity, re-
duced intensity of the 68-kD paxillin was seen upon collagen 
stimulation of FLNa-silenced cells compared with their 
matched control cells. Moreover, pretreatment of MDA-231-
ErbB2 cells with 50 µM of the calpain inhibitor ALLN for 
22 h followed by a subsequent 5-min stimulation with de-
graded collagen revealed a significant inhibition of FA protein 
cleavages (Fig. 6 B, right). These results confirmed an increase 
of FA protein cleavage upon FLNa silencing (e.g., percentage 
cleaved FAK was 16.68 ± 5.77% and 61.83 ± 8.87% for con-
trol and FLNa-silenced cells, respectively, whereas the per-
centage of cleaved paxillin was 23.88 ± 6.79% and 53.57 ± 
7.48% for control and FLNa-silenced cells, respectively; P < 
0.001). Similar results were observed when using BT-20 cell 
line (Fig. S5).
We then investigated the impact of calpain on FLNa- 
mediated FA turnover in BT-20 cells using the calpain inhibi-
tor ALLN. Cell exposure to 100 µM ALLN and nocodazole 
for 4 h followed by a washout reduced FA turnover in control 
cells (Fig. 6 C and Fig. S6), which is in agreement with a pre-
vious finding by Bhatt et al. (2002). Interestingly, no differ-
ence in FA turnover was seen between FLNa-silenced and 
control cells preexposed to ALLN. Under a similar condition, 
Western blot analysis confirmed a restoration of phospho-
protein levels of FAK-pY397 and paxillin-pY118 upon 
exposure to ALLN, which abolished the difference in FA 
turnover seen between FLNa-silenced and control cells (un-
published data). Together, these results indicate that calpain is 
required for microtubule-mediated FA complex disassembly 
and that inhibition of calpain activity abolished the regulatory 
effect of FLNa on FA turnover.
ALLN is a general calpain inhibitor that targets both the 
µ-calpain isoform (calpain 1) and m-calpain (calpain 2). Pre-
vious studies by Franco et al. (2004a,b) demonstrated that 
calpain 2 but not calpain 1 is critical for the cleavage of FA 
and cytoskeletal proteins, including FAK, paxillin, talin, and 
spectrin, as well for the regulation of membrane protrusion 
dynamics. We silenced calpain 2 in control and FLNa-silenced 
cells using a specific small interfering RNA (siRNA) sequence 
(Fig. 7 A and Fig. S2 B) and then followed FA formation and 
disassembly in live cells. Live fluorescence imaging of EYFP-
paxillin revealed a persistence of FAs for extended durations 
as well as decreased disassembly rates of FA after calpain 2 silenc-
ing in both control and FLNa-silenced cells (Fig. 7, B and C; 
and Videos 3 and 4). These results indicate that inhibition of 
calpain 2 by siRNA or ALLN (Videos 5 and 6) can prevent the 
difference seen in FA disassembly between FLNa-silenced and 
control cells, which further supports a calpain-dependent mech-
anism for FLNa function in the regulation of FA turnover.
FLNa promotes calpain activation via mitogen-activated 
protein kinase (MAPK) signaling
The MAPK cascade is central to both filamin and calpain sig-
naling. We investigated the impact of MAPKs on FLNa- 
induced calpain 2 activation using parental BT-20 cells (CTL), 
Published October 11, 2010
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Figure . FLNa regulates FA disassembly. (A) BT-20 cells expressing empty retroviral particles (PSR) or FLNa-specific shRNA (PSR-FLNa) were seeded 
on fibronectin- or collagen-coated dishes and grown at 70% confluence. Total protein extracts were probed using antibodies against the indicated  
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calcium fluxes and calcium-sensing receptor (Zhang and 
Breitwieser, 2005), we investigated whether a possible change 
in intracellular calcium after FLNa knockdown could account 
for calpain activation. However, no differences in intracellular 
calcium were detected between control cells and their matched 
FLNa-silenced cells in three independent experiments using 
the Fluo-4 NW calcium assay from Invitrogen (unpublished 
data). Together, these data argue for MAPK being a central 
regulator for coupling FLNa and calpain signaling to FA pro-
tein cleavage.
FLNa and talin may compete for calpain-mediated cleavage, 
and this impacts FA disassembly
It has been demonstrated that calpain regulates cell spreading 
(Potter et al., 1998) and motility (Carragher et al., 2003) via 
modulation of cleavage of FA and cytoskeletal protein sub-
strates (Glading et al., 2002). For instance, Franco et al. (2004b) 
reported that proteolysis of talin by calpain is the rate-limiting 
step for FA turnover. FLNa and talin have been shown to reg-
ulate integrin activation via a competitive binding to integrin 
cells expressing empty viral particles (PSR), FLNa shRNA–
expressing cells (PSR-FLNa), and their matched cells rescued 
with shRNA-resistant FLNa (PSR-FLNa+FLNa) and control 
FLNa-shRNA cells expressing empty plasmid used for FLNa 
rescue (PSR-FLNa+pcDNA; Fig. 8 A). Cells were serum 
starved and then stimulated with 5 ng/ml epidermal growth 
factor (EGF) for 10 min (predetermined to be the maximal 
induction of MAPK activity in this model; unpublished data). 
Interestingly, MAPK–extracellular signal-regulated kinase 
(ERK) activity and ERK phosphorylation (Fig. 8 B) were 
found to be significantly elevated in FLNa-silenced cells 
compared with control cells. The induction of MAPK activity 
was prevented by preexposure of cells to the MEK (MAPK–
ERK kinase) inhibitor UO126 or after reexpression of 
shRNA-resistant WT FLNa (P < 0.005; Fig. 8 B). Under 
similar conditions, FLNa silencing induced calpain activation 
that was prevented after cell pretreatment with UO126 or 
after reexpression of shRNA-resistant WT FLNa (P < 0.005; 
Fig. 8 C). Because FLNa has been shown to be required for 
calpain 2 activation via MAPK-dependent stimulation of 
proteins. Bar graph shows quantification of ratio of phosphorylated/total proteins (mean ± SD) from four independent experiments (*, P < 0.05).  
(B) Serum-starved control (PSR) and FLNa-silenced (PSR-FLNa) BT-20 cells were incubated with 10 µM nocodazole (NZ) for 4 h. Control untreated cells and 
treated cells at the indicated times after nocodazole washout were fixed and immunoassayed with anti–paxillin-pY118 or anti-FLNa. Three independent 
experiments were performed. Bar, 20 µm. (C) Quantification of FA areas using Volocity software. Data are expressed as the area of FAs per DAPI-stained 
nucleus and were obtained from at least 20 cells per condition. Quantifications show mean ± SD from three independent experiments as in B (*, P < 0.01). 
(D) Representative Western blots of FAK and paxillin during FA disassembly. BT-20 cell lysates were collected at the indicated times as in B and immuno-
blotted with anti–FAK-pY397 or anti–paxillin-pY118. Bar graphs represent the densitometry result as percentage of density of PSR control at 0 min 
(which is 100%) from four independent Western blots. MM, molecular mass.
 
Figure . Time-lapse quantification of FA dynamics after FLNa inhibition. (A) Control (PSR) and FLNa-silenced (PSR-FLNa) BT-20 cells transfected 
with EYFP-paxillin were plated on chamber slide, stimulated with 10 ng/ml EGF, and then analyzed by time-lapse spinning disk confocal microscopy.  
Representative frames are shown. (B) Enlargements of the boxed regions of A showing white arrows that indicate positions of paxillin-containing FAs.  
(C) Quantification of EYFP-paxillin persistence in FAs. Duration measurements were quantified by counting the amount of time lapsed between the first 
and last frames in which an individual adhesion was followed. (D) Rate constants of EYFP-paxillin disassembly at individual adhesions were calculated  
as described in Materials and methods. (C and D) Quantifications show the mean ± SD from three independent experiments (*, P < 0.01). Bars: (A) 15 µm; 
(B) 5 µm.
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both cell invasion and migration, whereas talin silencing in-
hibited these phenotypes (Fig. 9, C and D; also reported in 
Fig. 3, B–D).
To further investigate whether FLNa may exert an indi-
rect effect on the dynamics of FA through competition for 
calpain-mediated proteolysis, we used a noncleavable form of 
GFP-FLNa in which the calpain-targeting sequence (TYA: 
1762–1764 aa) was deleted (GFP–FLNa-). Although this 
mutation did not completely prevent FLNa cleavage, the levels 
of smaller molecular weight degradation products were found 
to be significantly reduced (Gorlin et al., 1990; Mammoto 
et al., 2007). We compared FA disassembly in FLNa-silenced 
BT-20 cells transfected with either GFP-FLNa WT (GFP–
FLNa-WT) or GFP–FLNa- mutant. Interestingly, BT-20 
cells expressing siFLNa GFP–FLNa- mutant showed a 
(Kiema et al., 2006). Therefore, we investigated whether FLNa 
competes with other FA proteins for calpain cleavage.
We examined calpain-mediated cleavage activity on con-
trol and talin-silenced BT-20 cells stimulated with degraded 
collagen. The levels of full-length FAK, Src, and paxillin were 
found to be elevated in talin-silenced cells compared with 
control cells (Fig. 9 A). These results indicate that inhibition 
of talin can prevent the cleavage of FAK, Src, and possibly 
paxillin. Noticeable, FLNa level was reduced upon knock-
down of talin, suggesting an induction of FLNa cleavage. 
Quantification of the cleavage products of FAK, Src, and pax-
illin after stimulation with degraded collagen for 5 min con-
firmed an increase in protein cleavage upon knockdown of 
FLNa and a decrease in protein cleavage upon knockdown of 
talin (P < 0.005; Fig. 9 B). Moreover, FLNa silencing promoted 
Figure . Regulation of FA turnover by FLNa is calpain dependent. (A) Control (PSR) or FLNa-silenced (PSR-FLNa) BT-20 and MDA-231-ErbB2 cells 
were grown to confluence, and total lysates were used for the luminescent Calpain-Glo protease assay. The relative luminescence units (RLU) were aver-
aged and normalized to the amount of proteins in cell lysates. The experiments were repeated four times, and the results are expressed as mean ± SD.  
(B) Control (PSR) or FLNa-silenced (PSR-FLNa) MDA-231-ErbB2 cells were cultured on 10-cm dishes and stimulated or not with degraded type I collagen 
(De.Collagen) for the indicated times. Where indicated, cells were treated with 50 µM of calpain inhibitor ALLN (22 h). Lysates were prepared at the indi-
cated time points and analyzed by Western blotting using the corresponding antibodies. Control indicates unstimulated. Bar graph shows quantification 
and comparison of FA protein cleavage (mean ± SD) at the 5-min time point after degraded collagen stimulation from Western blot results generated 
from five independent experiments (*, P < 0.001). CT, C terminus; MM, molecular mass; NT, N terminus. (C) Control (PSR) and FLNa-silenced (PSR-FLNa) 
BT-20 cells were incubated with 10 µM nocodazole (NZ) plus 100 µM ALLN for 4 h followed by a washout. Bar graph shows the area of FAs per DAPI-
stained nucleus (mean ± SD) obtained from five fields per condition and from three independent nocodazole washout assays. CTL, untreated.
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BT-20 cells with a slight but reproducible inhibition of 
calpain-mediated cleavage of FA proteins (Fig. 10 D) and FA 
turnover (Fig. S7) compared with FLNa-silenced BT-20 cells 
expressing EGFP alone.
DISCUSSION
The function of filamin in cancer cell migration and invasion 
is not fully understood. In this study, we report a correlation 
between low FLNa levels and breast cancer progression using 
a cancer TMA from patients with progressive disease, including 
lymph node–negative and –positive breast cancer. The inverse 
correlation between FLNa expression and cancer progression 
was further supported by results of the migration and invasion 
assays in alternative breast cancer cell lines, as well as in ortho-
topic breast cancer xenograft models in which down-regulation 
of FLNa is found to promote cancer cell invasion and metas-
tasis formation. These results were unexpected in light of pre-
vious studies showing a positive association between FLNa 
greater reduction of phosphorylation levels of FAK-pY397 
and paxillin-pY118 compared with cells expressing siFLNa 
GFP–FLNa-WT (more evident at 15 and 30 min after no-
codazole washout; Fig. 10 A). We then compared the cleavage 
of FA proteins after rescue of FLNa-silenced cells with either 
GFP–FLNa-WT or GFP–FLNa- mutant. BT-20 siFLNa-
silenced cells rescued with GFP–FLNa- mutant showed a 
pronounced reduction of native FAK compared with BT-20 
siFLNa rescued with GFP–FLNa-WT. Moreover, transfec-
tion of GFP–FLNa-WT in FLNa knockdown BT-20 cells 
successfully rescued cell invasion to control levels, whereas 
GFP–FLNa- had no effect on rescue of this phenotype 
(Fig. 10 C). These data further indicate that cleavage of 
FLNa by calpain impacts the cleavage of other FA proteins 
such as FAK and can affect cell invasion. Moreover, transient 
expression of FLNa 14–16 repeats (enhanced GFP [EGFP]–
FLNa 14–16), which includes hinge 1 (calpain-targeting se-
quence), partially rescued the phenotype in FLNa-silenced 
Figure 7. Time-lapse quantification of FA dynamics after calpain  inhibition. (A) Western blot showing calpain 2 siRNA (sequence 1) efficiency 
in control and FLNa-silenced BT-20 cells. GAPDH was used as an internal control. MM, molecular mass. (B) Control (PSR) or FLNa-silenced (PSR-FLNa)  
BT-20 cells stably expressing EYFP-paxillin were transfected with calpain 2 siRNA, stimulated with EGF, and then analyzed by time-lapse spinning disk 
confocal microscopy. White arrows show the positions of paxillin-containing FAs. Four independent experiments were performed, and representative 
frames are shown. Bar, 5 µm. (C, left) Quantification of the persistence of EYFP-paxillin in control and FLNa knockdown cells. (right) Quantification of 
EYFP-paxillin disassembly. Quantifications show the mean ± SD from three independent experiments.
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breast cancer. However, they bring up challenging questions 
on how the FLNa signaling nexus regulates breast cancer cell 
invasion. Using alternate cancer models, we observed that 
down-regulation of FLNa can increase cancer cell migration 
via regulation of FA turnover, at least in part because of acti-
vation of calpain activity and FA protein cleavage. A previous 
study demonstrated that cell spreading associated with FLNa 
knockdown is partially compensated by competing proteins 
that bind to -integrin, including talin, which can activate 
integrin (Kiema et al., 2006). Suppression of FLNa could in-
crease talin binding to integrin  tail and thus enhance integ-
rin activation and cell motility. In addition to the competition 
between FLNa and talin for integrin  tail, our data suggest a 
second level of competition between FLNa, talin, and other 
FA proteins such as FAK and paxillin via calpain cleavage; this 
could impact the regulation of FA turnover (Fig. S8).
Molecular mechanisms of FA disassembly, unlike FA as-
sembly (Raftopoulou and Hall, 2004), are not fully defined. 
Our biochemical and real-time imaging results revealed that 
FLNa-silenced cells have elevated calpain activity and accel-
erated FA disassembly compared with their matched control 
expression levels and cell migration (Cunningham et al., 1992; 
Alper et al., 2009; Baldassarre et al., 2009). However, they are 
in agreement with other studies showing that FLNa overex-
pression in FLNa-deficient M2 cells (Cunningham et al., 1992; 
Nagano et al., 2004) or in mouse cortical neurons (Sarkisian 
et al., 2006) inhibited cell migration, and an association of 
FLNa with carcinoembryonic antigen-related cell adhesion 
molecule has been shown to strengthen cell–cell contact and 
thus acts negatively on tumor cell invasion and metastasis for-
mation (Klaile et al., 2005). In humans, FLNa gene duplica-
tions rather than loss of function mutations were found in a 
patient with a severe form of X-linked periventricular het-
erotopia (Fink et al., 1997). Moreover, Lin et al. (2007) reported 
decreased intracellular levels of an endogenous fragment of 
FLNa (repeat 7–15) in patients with advanced prostate cancer, 
whereas another study found low levels of endogenous FLNa 
in advanced and aggressive prostate cancer compared with 
benign tissues (Varambally et al., 2005).
Our results on breast cancer tissues support a potential 
utility of filamins as signature biomarkers for invasive cancers 
because FLNa levels were significantly decreased in invasive 
Figure . FLNa down-regulation stimulates 
calpain activity via MAPK activation.  
(A) Lysates of parental BT-20 cells (CTL), cells 
expressing empty viral particles used for FLNa-
shRNA expression (PSR), FLNa shRNA–expressing 
cells (PSR-FLNa), and their matched cells  
rescued with shRNA-resistant FLNa (PSR-
FLNa+FLNa) or empty plasmid used for FLNa 
rescue (PSR-FLNa+pcDNA) were immunoblot-
ted with FLNa-specific antibody. GAPDH was 
used as an internal control. (B) Control BT-20 
cells (CTL), BT-20 cells expressing empty viral 
particles (PSR), BT-20 cells expressing FLNa-
shRNA alone (PSR-FLNa, CTL), FLNa-shRNA 
cells pretreated for 2 h with 10 µM UO126 
(PSR-FLNa, UO126), FLNa-rescued FLNa shRNA 
cells (PSR-FLNa, FLNa), and PSR-FLNa cells 
expressing empty plasmid (PSR-FLNa, pcDNA) 
were serum starved and then stimulated or 
not with 10 ng/ml EGF for 10 min. Total cell 
extracts were assayed for kinase activity (left) 
by immunocomplex kinase assay using anti-
ERK2 for immunoprecipitation and MBP as 
kinase substrate in presence of -[32P]ATP as 
described in Materials and methods or by 
Western blotting using anti–phospho-ERK1/2 
(right). The radioactivity incorporated into 
MBP was quantified from the excised MBP 
bands by Cerenkov counting. (C) Samples as in 
B were used to determine calpain activity  
using the luminescent Calpain-Glo protease 
assay as described in Materials and methods. 
(B and C) Results are expressed as the  
mean ± SD of three independent experiments 
(*, P < 0.005). MM, molecular mass.
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cells. This observation is significant because FA formation at 
the leading edge and disassembly at the trailing edge of a motile 
cell are established to be critical events for the initiation and 
maintenance of cell locomotion. Previous studies have re-
ported that binding of FLNa to integrin can inhibit cell mi-
gration without affecting FA formation or fibronectin matrix 
assembly (Pfaff et al., 1998; Calderwood et al., 2001). More-
over, a study by Bhatt et al. (2002) reported that calpain inhi-
bition had no effect on microtubule targeting of FA sites but 
rather stabilized peripheral adhesive complexes and inhibited 
microtubule-mediated turnover of FA after nocodazole wash-
out. Therefore, although our data support a functional con-
nection between FLNa levels and FA disassembly kinetics, it 
remains to be determined whether such a connection occurs 
in vivo. In particular, a recent study using live-cell microscopy 
reported that FAs in cells embedded in a three-dimensional 
matrix are not readily detected and that FA proteins such as 
vinculin, paxillin, talin, FAK, p130Cas, -actinin, and zyxin 
do not seem to form aggregates but are diffusely distributed 
throughout the cytoplasm (Fraley et al., 2010). Despite the 
absence of detectable FAs, FA proteins were still able to mod-
ulate cell motility by affecting protrusion activity and extra-
cellular matrix remodeling in a manner that is distinct from 
cells grown on two-dimensional substrates.
Our data also support a role of calpain in FLNa-induced 
regulation of FA cleavage because FLNa silencing led to in-
creased proteolysis of talin and other FA proteins such as FAK 
and paxillin. Calpains regulate the dynamics of both integrin-
mediated adhesions and actin-based membrane protrusions 
(Perrin and Huttenlocher, 2002), but the molecular mecha-
nisms underlying this regulation remain partially understood. 
Cleavage of specific FA proteins by calpain can alter the com-
position of adhesion complexes, thus allowing dynamic re-
cruitment and anchoring properties of the cell cytoskeleton. 
Of relevance to our finding, Franco et al. (2004b) reported a 
role for calpain in the turnover of integrin-mediated cell adhe-
sion via talin proteolysis. In particular, this study demonstrated 
that calpain-mediated proteolysis of talin is a rate-limiting 
step during FA turnover. In line with these findings, our re-
sults support that FLNa and talin also compete for cleavage by 
the calpain protease because FLNa silencing led to increased 
proteolysis of talin, as well as of other FA proteins such as 
FAK and paxillin. It is intriguing to note that calpain action is 
primarily caused by its ability to modify rather than degrade 
its substrates. Previous studies indicated that calpain cleavage 
products such as the talin head domain can regulate integrin 
activation and FA turnover (Franco et al., 2004b; Goksoy et al., 
2008; Huang et al., 2009). More recently, a study reported that 
cleavage of FAK by calpain can also regulate adhesion dy-
namics (Chan et al., 2010). In the case of FLNa, calpain in-
duced a rapid cleavage of the protein at hinge 1 (between aa 
1762 and 1764) generating fragments of 190 and 100 kD 
(Kiema et al., 2006). A 10-kD small fragment can also be gen-
erated from the end of the 100 kD (cleavage of FLNa sub-
fragment at hinge 2) after longer calpain digestion. These 
cleavage kinetics indicated that hinge 1 is a predominant first 
cleavage site (1 min after incubation with calpain, whereas 
hinge 2 cleavage was seen only 5 min after incubation with 
calpain; Gorlin et al., 1990). In our study, transfection of FLNa 
knockdown cells with the noncleavable form of GFP–FLNa- 
(which has a deletion in the calpain-targeting sequence lo-
cated in hinge 1) failed to rescue FA turnover or cell invasion 
as we observed with the WT FLNa. Therefore, mutation of 
this cleavage site is critical to regulate the competition between 
FLNa and other calpain substrates. In support of this hypoth-
esis, expression of FLNa 14–16 repeats (which includes hinge 1) 
in FLNa-silenced cells rescued, although only partially, the 
reduced cleavage of FA proteins and FA turnover observed 
after FLNa silencing. This partial rescue could possibly be ex-
plained by low efficiency of transient transfection or a re-
quirement of full FLNa protein for optimal interaction with 
its partners. Moreover, it is not excluded that the partial res-
cue may be contributed by the short half-life of the exoge-
nous EGFP–FLNa 14–16 fusion protein, which we found to 
be very unstable in BT-20 cells compared with control cells 
expressing EGFP alone (unpublished data).
Moreover, recent studies postulated that FLNa cleavage 
fragments can also function as a signaling integrator of pro-
teolytic peptides and their generation could be regulated by 
phosphorylation/dephosphorylation (Jay et al., 2004; García 
et al., 2006). FLNa phosphorylation on Ser2152 by Pak1 
(p21-activated kinase 1; Vadlamudi et al., 2002), protein kinase 
A (Jay et al., 2004), and ribosomal S6 kinase (Woo et al., 2004) 
has been implicated in inducing FLNa resistance to calpain 
cleavage and in mediating stimulation of membrane ruffle 
formation and cell migration, respectively. Furthermore, 
Mammoto et al. (2007) demonstrated that FLNa regulates 
p190RhoGAP translocation to lipid rafts and Rho activation, 
actions which were mediated by calpain cleavage of FLNa. 
Therefore, FLNa and talin can allow the reorganization of in-
tegrin links to actin and/or dynamic recruitment of selective 
substrates for calpain cleavage; the resulting fragments can 
modulate the process of actin reorganization, cell spreading, 
and cell migration.
The regulation of calpain 2 by FLNa opens up a challeng-
ing question on the mechanism by which this is accomplished. 
FLNa and several FA proteins can act as scaffolding proteins 
via multiple protein–protein interactions. One candidate we 
have investigated is the MAPK–ERK pathway, which regu-
lates both FLNa (Awata et al., 2001; Hjälm et al., 2001; Zhang 
and Breitwieser, 2005; Onoprishvili et al., 2008) and calpain 2 
(Glading et al., 2001, 2004) activities, as well as calpain 2 co-
localization with FA proteins in FA sites (Beckerle et al., 
1987). FLNa regulates MAPK activity via interaction with 
several mitogen-activated proteins, including MAPK kinase 4 
(MKK-4/SEK-1; Marti et al., 1997), or modulation of the 
activity of guanine nucleotide exchange factors of the Ras–
MAPK pathway (Gorlin et al., 1990; Zhu et al., 2007). We 
observed a high MAPK activity and ERK phosphorylation in 
FLNa-silenced cells compared with control cells. This induc-
tion of MAPK–ERK activity was sufficient to stimulate cal-
pain activity and was prevented by cell exposure to the MEK 
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Figure . FLNa and talin are competitive substrates for cleavage by calpain and differentially regulate breast cancer cell invasion. (A) Con-
trol (PSR) and talin-silenced (PSR-Talin) BT-20 cells were cultured on 10-cm dishes and stimulated with degraded type I collagen (De.Collagen) to promote 
calpain-mediated cleavage of FA proteins. Control indicates unstimulated. Cell lysates were immunoblotted with the indicated antibodies. CT, C terminus; 
MM, molecular mass; NT, N terminus. (B) Quantification and comparison of FA protein cleavage (mean ± SD) at 5-min time point after degraded collagen 
stimulation from Western blot results of three independent experiments as in A and Fig. S5 B (*, P < 0.005). (C) Invasion of control (PSR), FLNa-silenced 
(PSR-FLNa), and talin-silenced (PSR-Talin) BT-20 cells using the Boyden chamber assay as described in Materials and methods. The bar graph shows the 
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progression. In conclusion, our data further support FLNa par-
ticipation as a scaffolding signaling molecule to link the cell 
cytoskeleton remodeling to FA dynamics.
MATERIALS AND METHODS
Antibodies and reagents. Antibody to paxillin was purchased from 
Thermo Fisher Scientific. Monoclonal antibody to FLNa N-terminal por-
tion (MCA464ST) was obtained from AbD Serotec. A polyclonal antibody to 
FLNb was obtained from Abcam. Antibodies to phospho-FLNa-Ser2152 and 
phospho-ERK1/2 were purchased from Cell Signaling Technology. Anti-
bodies to FAK (A-17) and FAK (C-20) were purchased from Santa Cruz 
inhibitor UO126 or reexpression of FLNa in FLNa-silenced 
cells. In contrast, immunostaining of phospho-ERK did not 
reveal any obvious changes in subcellular localization, suggest-
ing a global activation of ERK pathway upon FLNa silencing.
MAPK–ERK activation has a broad implication on cellular 
processes and can impact multiple signaling pathways in addi-
tion to calpains. For example, FLNa down-regulation has been 
reported to promote matrix metalloproteinase secretion (Zhu 
et al., 2007), an additional mechanism that can contribute to 
explain the association of FLNa down-regulation and cancer 
quantification of cell invasion results as the mean ± SD of four independent experiments and five fields per condition (*, P < 0.005; **, P < 0.01).  
Representative images of invasive cells on the membrane are shown. (D) Bar graph shows the quantification of cell migration analyzed by the wound 
healing assay. Control (PSR), FLNa-silenced (PSR-FLNa), and talin-silenced (PSR-Talin) BT-20 cells were wounded and monitored over 48 h to determine 
the rate of migration into the scratched area. The experiment was repeated four times, and results are expressed as mean ± SD. Representative images  
of the wound captured at different time point are shown. The vertical black lines delimit the wounded regions at different time points. Bars: (C) 150 µm; 
(D) 200 µm.
 
Figure 0. Cleavage of FLNa regulates 
FA turnover and cell invasion. (A) BT-20 
siFLNa cells were transfected with construct 
either expressing GFP-tagged FLNa WT (GFP–
FLNa-WT) or GFP-tagged FLNa mutant resis-
tant to calpain cleavage (GFP–FLNa-) and 
assayed for nocodazole (NZ)-based FA disas-
sembly. Cells were untreated (control) or incu-
bated with 10 µM nocodazole for 4 h. Cell 
lysates were collected at the indicated times 
and immunoblotted with anti–FAK-pY397 or 
anti–paxillin-pY118. (B) BT-20 siFLNa cells 
transfected with either GFP–FLNa-WT or GFP–
FLNa- were cultured on 10-cm dishes and 
stimulated or not with degraded type I col-
lagen (De.Collagen) for the indicated times. 
Where indicated, cells were treated with 50 µM 
of calpain inhibitor ALLN (22 h). Lysates  
were prepared at the indicated time points 
and analyzed by Western blotting using the 
corresponding antibodies. Control indicates 
unstimulated. NT, N terminus. (C) Control 
BT-20 cells, BT-20 siFLNa cells, and BT-20 siFLNa 
cells expressing GFP–FLNa-WT or GFP–FLNa- 
were placed in the top layer of Boyden migra-
tion chamber, and after 48 h, cells migrated 
through the chamber to the bottom mem-
brane were measured. The graph represents 
the mean ± SD from four independent experi-
ments (*, P < 0.005). (D) FLNa-silenced BT-20 
cells were transfected with construct either 
expressing EGFP-tagged FLNa 14–16 repeats 
(EGFP-FLNa (14–16)) or expressing EGFP 
alone, stimulated or not stimulated with de-
graded type I collagen. Cell lysates were im-
munoblotted with the indicated antibodies. 
Bar graph shows quantification of cleavage of 
FAK (mean ± SD) from three independent 
experiments. MM, molecular mass.
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20 mg/ml pepstatin A, 1 mM PMSF, and protease inhibitor cocktail (Roche) 
as we described previously (Benlimame et al., 2005). Blots were detected 
using the appropriate antibodies, and signal was detected with horseradish 
peroxidase–conjugated secondary antibodies and enhanced chemilumines-
cence detection system. When indicated, membranes were subsequently 
stripped for reprobing. Immunoblots were quantified by using ImageJ 
(National Institutes of Health) software.
FA disassembly assay. The assay for FA disassembly and reformation after 
nocodazole treatment has been described previously (Ezratty et al., 2005; Yeo 
et al., 2006). Serum-starved cells were grown on glass coverslips and treated 
with 10 µM nocodazole for 4 h to completely depolymerize microtubules. 
The drug was washed out with serum-free media, and cells were fixed and 
processed for immunofluorescence at different intervals. Cells were stained 
with vinculin, FAK-pY397, paxillin-pY118, and/or -tubulin.
Indirect immunofluorescence analysis. The cells were fixed with para-
formaldehyde, permeabilized, and labeled for immunofluorescence essen-
tially as we described previously (Yen et al., 2002; Benlimame et al., 2005). 
Slides were viewed in a fluorescent microscope (Axiophot; Carl Zeiss, Inc.) 
equipped with a 63× Plan-Apochromat objective and selective filters. Images 
were acquired from a cooled charge-coupled device camera (Retiga 1300; 
QImaging) and displayed on a high resolution monitor. Images were ana-
lyzed by a Northern Eclipse Image analysis system (Carl Zeiss, Inc.).
Invasion assay and migration assay. Cell invasion assays were performed 
using 8-µm porous chambers coated with Matrigel (BD) according to the 
manufacturer’s recommendations. Cell migration was assayed using the quali-
tative wound healing assay (Benlimame et al., 2005). Each experiment was 
performed at least three times, and results are expressed as mean ± SD. Statis-
tical significance was analyzed using the Student’s t test.
Phagokinetic tracks assay. To analyze cell motility, the phagokinetic track 
assay was conducted as described previously (Albrecht-Buehler, 1977). Gold 
colloid particles were prepared, and glass coverslips were coated with the 
particles. BT-20 cells were plated on the gold particle–coated glass coverslips, 
cultured for 24 h, and then fixed with 3.5% formaldehyde. The phagokinetic 
range was observed and photographed by brightfield microscopy. The area of 
migration was calculated by ImageJ software.
Calpain activity. Cells were grown to confluence and lysed with radioim-
munoprecipitation assay lysis buffer. The lysate was cleared of debris and 
used for the Calpain-Glo protease assay (Promega) according to the manu-
facturer’s protocol. The relative luminescence was averaged over 10 s, back-
ground-subtracted, and normalized to the amount of protein in the lysate 
(Boehmerle et al., 2007). Statistical significance was analyzed using the 
Student’s t test.
MAPK kinase assay. Serum-starved cells at 70% confluence were stimu-
lated with 5 ng/ml EGF for 10 min (this time point was chosen based on 
a preliminary time-response study indicating a maximum MAPK activity 
10 min after EGF stimulation followed by a rapid decrease in activity). Cells 
were then washed with cold PBS and lysed with a lysis buffer (containing 
50 mM Hepes, 150 mM NaCl, 5 mM MgCl2, 0.5 mM EGTA, 0.1% Triton 
X-100, 10% glycerol, 0.5 mM DTT, 1 mM Na3VO4, 1 mM PMSF, 5 mg/ml 
aprotinin, and 5 mg/ml leupeptin) and immunoprecipitated using a poly-
clonal anti-ERK2 antibody (Santa Cruz Biotechnology, Inc.). The immuno-
precipitates were washed in Triton X-100–only lysis buffer, followed by 
kinase buffer (10% glycerol, 20 mM Hepes, 10 mM MgCl2, 10 mM MnCl2, 
and 100 mM NaCl). Immunoprecipitates were then incubated for 15 min at 
32°C in 30 µl of kinase buffer containing 4 µg of myelin basic protein (MBP), 
20 µM ATP, and 5 µCi/nmol -[32P]ATP (3,000 Ci/mmol). Reactions were 
stopped with 2× SDS-PAGE sample buffer, resolved by SDS-PAGE, stained 
with Coomassie blue, and visualized by autoradiography, and the radioactiv-
ity incorporated into MBP was determined by Cerenkov counting of the 
Biotechnology, Inc. Antibodies to FAK (clone 4.47), FAK-pY397, and paxil-
lin-pY118 were purchased from Invitrogen. Antibody to Src (clone GD11) 
was purchased from Millipore. Antibodies to vinculin (clone hVLN-1) and 
talin (clone 8D4) were obtained from Sigma-Aldrich. Antibody to GAPDH 
was obtained from Cedarlane, and antibody to -tubulin was purchased from 
Abcam. Fibronectin, collagenase type I, 10× RPMI 1640, and nocodazole 
were purchased from Sigma-Aldrich. Secondary antibodies for immunofluo-
rescence were obtained from Jackson ImmunoResearch Laboratories, Inc. 
Collagen was obtained from BD. Calpain inhibitor experiments were per-
formed using calpain inhibitor 1 (EMD).
Cell culture. Breast adenocarcinoma cell lines MCF-7, MDA-231, and 
BT-20 were obtained from American Type Culture Collection and main-
tained in RPMI 1640 (Mediatech, Inc.) supplemented with 10% FBS and 
supplemented with penicillin and streptomycin antibiotics. ErbB-2 receptor 
was overexpressed using a bicistronic retrovector that coexpressed ErbB2 
receptor with EGFP (Yen et al., 2002).
Collagen matrix preparation. Polymerized collagen gels (1.4 mg/ml final 
concentration) were prepared by neutralization of an 8/10 vol of collagen solu-
tion with 1/10 vol of 10× RPMI 1640 concentrate, 1/10 vol of 0.1 M NaOH, 
and 1/40 vol of 7.5% NaHCO3, and then 1 vol of 1× DME was added and in-
cubated at 37°C for 24 h. Degraded type I collagen was prepared by incubating 
polymerized collagen gels with 2.5 mg/ml collagenase type I for 30 min at 37°C. 
After digestion, collagenase activity was inhibited by the addition of an equal 
volume of 1× DME containing 10% FBS (Carragher et al., 1999).
Generation of stable FLNa and talin knockdown cells. Stable FLNa 
and talin knockdown cells were generated in a polyclonal population 
as described previously (Benlimame et al., 2005). FLNa (available from 
GenBank/EMBL/DDBJ under accession no. NM_001456.3) sequence 1, 
5-GGGCTGACAACAGTGTGGTGC-3 (targeting nt 3323–3343); and 
sequence 2, 5-GGTGCTGCCTACTCATGATGC-3 (targeting nt 4663–
4683; Huang et al., 2006); and talin (available from GenBank under accession 
no. NM_006289.3) sequence 1, 5-GACTGTCACTGACATGCTCAT-3  
(targeting nt 672–692, not reported before); and sequence 2, 5-TCGT-
GAGGGTACTGAAACT-3 (targeting nt 6169–6187; Manevich et al., 2007) 
are the target sequences used for stable knockdown of FLNa and talin. Each 
sequence was cloned as inverted repeats into PSR puromycin vector accord-
ing to the manufacturer’s instructions (Oligoengine).
Construction of plasmid. The DNA segment encoding human FLNa res-
idues 1534–1875 (repeats 14–16) was amplified from pEGFP-C1-FLNa WT. 
The 5 primer 5-GCAAGCTTGCCCCTTCAAGGTCAAGG-3 and 
3 primer 5-GCTCTAGAGAGGCCAGGCCCATA-3 were used to am-
plify a 1-kbp PCR product that was inserted into the HindIII and XbaI sites 
of the pEGFP-C1 plasmid.
For WT FLNa rescue, we designed an siRNA-resistant FLNa by intro-
ducing a silent mutation at position 3330 (gac→gat) using standard site- 
specific mutagenesis assay. The cDNA clone was confirmed by sequencing 
using a dye primer cycle sequencing kit (PerkinElmer) and DNA sequencer 
(ABI 377; PerkinElmer).
Transfection of siRNA. Calpain 2 (available from GenBank under accession 
no. NM_001748.4) sequence 1, 5-GACTTCACCGGAGGCATTG-3 (tar-
geting nt 840–858, not reported before); and sequence 2, 5-GTACCTCAAC-
CAGGACTAC-3 (targeting nt 302–320; Franco et al., 2004b; Benetti et al., 
2005) are the target sequences used for transient knockdown of calpain 2. 100 nM 
of siRNA oligonucleotides (Thermo Fisher Scientific) was incubated with 
DharmaFECT1 (Thermo Fisher Scientific) in Opti-MEM I reduced serum me-
dium (Invitrogen) according to the manufacturer’s instructions.
Western blot analysis. Western blot analyses were performed on total 
cell extracts from exponentially growing cells collected by scrapping into 
modified radioimmunoprecipitation assay lysis buffer supplemented with 
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secondary antibody. Diaminobenzidine was used as a chromogen, and slides 
were counterstained with hematoxylin before mounting. All staining proce-
dures were performed according to the manufacturer’s recommendations. 
A multitissue control TMA slide containing samples of prostate, colon, and 
breast was screened using the primary antibody or normal mouse 1:200 
prediluted serum (Ventana Medical Systems, Inc.) as positive and negative 
controls, respectively.
Manual scoring of FLNa and data analysis. All TMA cores were as-
signed a diagnosis (i.e., benign, in situ carcinoma, invasive breast cancer, and 
lymph node metastatic breast cancer) by the study pathologist. All manual 
scoring was performed on a microscope (×100; BX41; Olympus). The pro-
tein expression was evaluated using a categorical scoring method ranging 
from 0 to 3 (0, negative; 1, weak; 2, moderate; and 3, strong). Moreover, the 
extent of expression was quantified into four subgroups of <25, 25–50, 50–75, 
and 75–100%. A final score was obtained by multiplying the intensity and 
extent of immunostaining within each sample. All data analyses were per-
formed by means of the computer-based statistical package of SPSS version 
5.1 (SPSS, Inc.) for Windows. Results were reported as mean ± SEM. Differ-
ences among the three groups (benign, in situ carcinoma, and invasive carci-
noma) were compared with one-way analysis of variance and the post-hoc 
Tukey honestly significant difference test for multiple comparisons. A p-value 
of ≤0.05 was considered statistically significant.
Online supplemental material. Fig. S1 shows the expression of FLNb and 
phospho-FLNa in breast cancer patients with progressive disease. Fig. S2 de-
picts Western blot analysis showing efficient knockdown of FLNa, talin, and 
calpain 2 by targeting different sequences. Fig. S3 shows that FLNa regulates 
FA disassembly. Fig. S4 shows cleavage of FAK in response to treatment with 
degraded type I collagen. Fig. S5 shows the effect of FLNa inhibition on cal-
pain activity. Fig. S6 shows that calpain inhibitor ALLN abolishes the effect of 
FLNa in regulation of FA disassembly. Fig. S7 shows that expression of FLNa 
14–16 repeats partially rescues the effect of FLNa knockdown in regulation 
of FA disassembly. Fig. S8 shows a schematic representation of FLNa regu-
lation of cell migration. Videos 1–3 show FA dynamics of BT-20 control, 
FLNa-silenced, and calpain 2–silenced cells, respectively. Video 4 shows FA 
dynamics of BT-20 cells with FLNa and calpain double knockdown. 
Videos 5 and 6 show FA dynamics of ALLN-treated BT-20 control and 
FLNa-silenced cells, respectively. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20100433/DC1.
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